Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Pharmacyclics, Inc., which developed ibrutinib, sponsored the clinical trial.
Clinical trial collaborators and co-authors are Jorge Romaguera, M.D., also of MD Anderson's Department of Lymphoma and Myeloma, Simon Rule, M.D., of Derriford Hospital, Plymouth, United Kingdom; Peter Martin, M.D., Weill-Cornell Medical College, New York; Andre Goy, M., John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, N.J.; Rebecca Auer, M.D., Barts Cancer Institute, Queen Mary University of London; Brad Kahl, M.D., University of Wisconsin School of Medicine, Madison, Wisc.; Wojciech Jurczak, M.D., Jagiellonian University, Krakow, Poland; Ranjana Advani M.D., Stanford University School of Medicine; Jesse McGreivy, M.D., Fong Clow, Sc.D., Michelle Stevens-Brogan, and Lori Kunkel, M.D. all of Pharmacyclics, and Kristie Blum, M.D. of The Ohio State University, Columbus, Ohio.
All academic institution co-authors receive research funding from Pharmacyclics. The company's co-authors all have an equity ownership in Pharmacyclics.
University of Texas M. D. Anderson Cancer Center
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Lymphoma / Leukemia / Myeloma category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
University of Texas M. D. Anderson Cancer Center. "Phase 2 Clinical Trial Of Ibrutinib Shows High Overall Response, Remissions In Patients With Resistant Mantle Cell Lymphoma." Medical News Today. MediLexicon, Intl., 20 Dec. 2012. Web.
7 Mar. 2014. <http://www.medicalnewstoday.com/releases/254134>
University of Texas M. D. Anderson Cancer Center. (2012, December 20). "Phase 2 Clinical Trial Of Ibrutinib Shows High Overall Response, Remissions In Patients With Resistant Mantle Cell Lymphoma." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/254134.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.